Viva Biotech Holdings

Research Viva Biotech Holdings (1873.HK) on Bullrun: market cap HKD 2.83B, P/E 17.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is HKD 2.83B; P/E is 17.1.

Peer valuation comparison

Latest P/E is 17.13x versus a Healthcare sector median of 21.75x (21.3% below).

Latest P/E is 17.13x versus a China median of 16.26x (5.3% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CNY 1.73BCNY 219.76MCNY 109.68M37.9%0.09CNY 1.09BCNY 1.33BCNY 4.00B
FY2024CNY 1.99BCNY 167.29MCNY 182.32M34.6%0.06CNY 941.71MCNY 1.28BCNY 3.80B
FY2023CNY 2.16B-CNY 116.11MCNY 195.57M34.3%-0.14CNY 1.04BCNY 1.90BCNY 3.69B
FY2022CNY 2.38B-CNY 528.48MCNY 136.51M34.3%-0.28CNY 678.57MCNY 2.82BCNY 3.60B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18HKD 2.83B17.1n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

YearDividends/share
FY20210.01 CNY

About Viva Biotech Holdings

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Viva Biotech Holdings's market cap?

Viva Biotech Holdings's market capitalization is HKD 2.83B.

What is Viva Biotech Holdings's P/E ratio?

Viva Biotech Holdings's price-to-earnings (P/E) ratio is 17.1.

What does Viva Biotech Holdings do?

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.